Gilead SciencesFRA:GIS -1.34%75 EBITDA Margin % is 50.42% as of Mar. 2026, which is 26% above its 10-year median of 40.10. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €82.28 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Gilead Sciences ranks better than 96.23% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gilead Sciences's EBITDA for the
three
months ended in Mar. 2026 was €3,035 Mil. Gilead Sciences's Revenue for the
three
months ended in Mar. 2026 was €6,020 Mil. Therefore, Gilead Sciences's EBITDA margin for the quarter that ended in Mar. 2026 was 50.42%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gilead Sciences EBITDA Margin % Related Terms
Gilead Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs AMGN, PFE, BMY: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a EBITDA Margin % of 50.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gilead Sciences and its competitors. This is 26% above median its historical median of 40.10. Over the past decade, Gilead Sciences' EBITDA Margin % has ranged from 15.42 to 63.24. According to the industry distribution chart, Gilead Sciences ranks #36 out of 955 companies in the Drug Manufacturers industry, placing it in the top 3.8%.
Is Gilead Sciences' EBITDA Margin % too high?
Gilead Sciences' current EBITDA Margin % of 50.42% is 26% above median its 10-year median of 40.10. Over the past 10 years, this metric has ranged from a low of 15.42 to a high of 63.24. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Gilead Sciences' value of 50.42% is 305.3% above this industry median. Based on the distribution chart, Gilead Sciences ranks #36 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' EBITDA Margin % compare to AMGN and PFE?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #36 out of 955 companies for EBITDA Margin %. This places Gilead Sciences in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Gilead Sciences' value of 50.42% is 305.3% above this benchmark. Historically, Gilead Sciences' own EBITDA Margin % has ranged from 15.42 to 63.24 over the past decade. While the company's 10-year median is 40.10 vs. the industry median of 12.44, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current EBITDA Margin % of 50.42% is 305.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current EBITDA Margin % is 50.42%, which is 26% above median its own 10-year median of 40.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.28, compared to a current price of €109.12 — trading 32.6% above its estimated fair value. The current EBITDA Margin % is 50.42%, which is 26% above median its 10-year median of 40.10 and 305.3% above the Drug Manufacturers industry median of 12.44. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current EBITDA Margin % is 50.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €109.12 is trading 32.6% above its estimated GF Value™ of €82.28.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
EBITDA Margin %: 50.42% (26% above median its 10-year median of 40.10)
GF Value™: €82.28 vs. price of €109.12 (32.6% above fair value)
Industry Position: 305.3% above the Drug Manufacturers median (#36 of 955)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
